Phase 4Recruiting

Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis

A Phase 4, Open-label, Multi-group Study of Rezdiffra® in Combination With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and Moderate to Advanced (F2-F3) Fibrosis, Administered According to Their Approved Labeling

Sponsor
Madrigal Pharmaceuticals, Inc. (Industry)
Enrollment
150 planned
Conditions
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions
Rezdiffra; Resmetirom; ACTOS/pioglitazone; FARXIGA/dapagliflozin
Ages
adults, older adults
Registry
NCT07848191

Full record on ClinicalTrials.gov

From the registry

To determine the safety of Rezdiffra (Resmetirom) when administered alongside common prescriptions for Diabetes Metellus (Farxiga/dapagliflozin \& Actos/pioglitazone)

Primary outcomes

  • Number and Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
  • Number and Percentage of Participants With TEAEs by Maximum Severity
  • Number and Percentage of Participants With TEAEs by Relationship to Study Medication

History

  1. Primary completion expected

  2. Last registry update

  3. Started

  4. Registered